About Us
We are an AI-driven company dedicated to transforming the biologics manufacturing industry, such as the production of antibodies, proteins, mRNA, cell & gene therapies, etc via T cells, CHO cells, NK cells, IPSCs and beyond. Our mission is to improve patients' access to the most innovative biologics, starting with the pressing challenges in R&D and manufacturing.
ChemT’s proprietary AI-driven virtual cell platform, CelMo, is the core of our innovation. Leveraging cutting-edge artificial intelligence, we design and deliver small molecules to make biologics production more robust and scalable. By optimizing the yield and efficacy of biological treatments, our platform offers a new approach to improving the performance and accessibility of life-changing therapies.
Our Platform
Our Breakthrough
Our flagship asset, Chemplify™ , is now commercially available for T cell therapeutic manufacturing. As a formulated anti-senescent solution containing patented small molecules, Chemplify™ achieves 5-10x higher T cell yield with significantly enhanced quality. Its proven in vitro and in vivo efficacy sets a new industry benchmark, enabling more effective and scalable immunotherapies for cancer. Our pipelines include more ground-breaking and innovative small molecules with novel targets, novel structures, and novel mechanisms of action for various cell activities.
Our Vision
Our vision goes beyond a single compound. We strive to replace traditional components like human serum and cytokines with small-molecule solutions that establish a chemically defined, consistent, and high-quality culture environment. Beyond T cells, our research and development pipeline focuses on optimizing CHO cells and advancing antibody generation, further amplifying the reach of our AI-driven biotech innovations. Other areas we work on include B cells, NK cells, stem cells, IPSC, etc.
